Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-NMMA and Teduglutide in Intestinal Lipoprotein Release
NCT03534661Phase 3
Key facts
- Status
- Completed
- Start
- Sep 2017
- Primary completion
- Mar 2019
- Countries
- 1
- Sponsor
- University Health Network
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Drugs
- teduglutide
- Conditions
- hyperlipidemia
01
Overview
Phase 3, randomised, single-blind trial of teduglutide in hyperlipidemia, sponsored by University Health Network. Started Sep 2017; status: completed.
02
Design
- Study design
- RandomizedSingle-blind
03
Who it enrols
Healthy, lean, non-diabetic adults aged 18-60 with normal glucose tolerance and no significant systemic disease.
04
Registry description
The gut is able to retain some fat for many hours after a fatty meal. The gut hormone glucagon-like peptide-2 (GLP-2) is known to release these fat stores in the gut, but it is not known how GLP-2 achieves this. One possibility is that GLP-2 increases blood flow in the gut. NG-monomethyl-L-arginine (L-NMMA) is a substance that inhibits nitric oxide synthase (an enzyme that helps make nitric oxide which increases blood flow). This protocol examines whether blocking gut blood flow with L-NMMA is able to prevent GLP-2 from releasing gut lipid stores. Healthy participants will be treated with a…
Beyond the preview
Go deeper on NCT03534661.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03534661.